

Express Mail No. EV074974211US

Date of Deposit: March 4, 2002

Attorney Docket No. 21402-179 (Cura-179)

RECEIVED
MAR 10 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Li, *et al.*
SERIAL NUMBER: 10/004,378 EXAMINER: Not Yet Assigned
FILING DATE: October 24, 2001 ART UNIT: 1646
FOR: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

Box IDS

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited references: A1-A3; and C87-C90; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 (Reference 21402-179). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

for Janine M. Susan, Reg. No. 46,119
Ivor R. Elrifi, Ph.D., Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 4, 2003

Express Mail Label No.: EV074974211US
Date of Deposit: March 4, 2003

Attny. Docket No.: 21402-179 (Cura-479)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Li, *et al.*
SERIAL NUMBER: 10/004,378

EXAMINER: Not Yet Assigned

FILING DATE: October 24, 2001

ART UNIT: 1646

FOR: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF
USING THE SAME

Box IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of a Partial International Search Report for PCT/US01/46057, which corresponds to the above-identified case. Accordingly, no fee or certification is believed required under 37 C.F.R. §1.97.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

RECEIVED
MAR 10 2003
TECH CENTER 1600/2900

Applicant: Li, et al.
U.S.S.N.: 10/004,378

Please charge any additional fees that may be due, or credit any overpayment of same, to
Deposit Account No. 50-0311 (Reference No. 21402-179).

Respectfully submitted,

for Janine M. Susan
Ivor R. Elrifi, Ph.D., Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 4, 2003

TRA 1768792v1

Express Mail No. EV074974211US

Date of Deposit: March 4, 2003

Page 1 of 1

Please type a plus sign (+) in this box

+

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/004,378
Filing Date	10/24/2001
First Named Inventor	Li
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	21402-179

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No
	A1	EP 0 915 155	Mochida Pharmaceutical Company, LTD.	05/12/1999	
	A2	EP 0 882 790	Sumitomo Electric Industries	12/09/1998	
	A3	WO 00/20435	Isis Pharmaceuticals, Inc.	04/13/2000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C87	Gomi, et al. (2000). "Molecular cloning of a novel membrane glycoprotein, pal, specifically expressed in photoreceptor cells of the retina and containing leucine-rich repeat." <i>Journal of Neuroscience</i> . 20(9): 3206-3213.
	C88	Mizushima, et al. (1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis (TRAF5)." <i>Gene</i> . 207(2):135-140.
	C89	Nakano, et al. (1997). "Human TNF receptor-associated factor 5 (TRAF5): CDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1Q32" <i>Genomics</i> . 42: 26-32.
	C90	Partial International Search Report for PCT/US01/46057. Mailed on 02/14/2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.